Clinical Biotechnology Company

Buy-in for this deal is $50k for Series A round. Adjacent companies (two) sold for $10B+ to Pfizer in less than 2 years, same advisors on board of this company. Please read the overview, and if interested, I can introduce you to the owner: — A28 Therapeutics is a clinical stage biotechnology company developing first in class targeted oncolytic peptides, targeting cell receptors common to multiple cancer types. Lead candidate, AT-101, has been clinically tested in more than 75 patients in Phase 1 and 2a clinical trials where it demonstrated a highly favorable safety profile as well as significant efficacy in the subset of patients with Stage 4 ovarian cancer with liver metastases. This finding is attributed to the unique biodistribution of the drug creating prolonged exposure in the liver. A28 purchased the lytic peptide platform including AT-101 and will repurpose the drug for Hepatocellular Carcinoma (HCC, liver cancer). The company is raising a $25M Series A to conduct Stage 1 of a two-stage trial to achieve accelerated approval in HCC. By conservative estimates, the liver cancer market alone would garner well over $3B in annual sales at peak. Highlights Strong efficacy signal: In Phase 2a, patients with late-stage, recurrent ovarian cancer with liver metastases treated with AT-101 plus chemotherapy had a 69% overall response rate (vs 17% for those treated with chemotherapy alone) and a 61% increase in overall survival Ability to select patients most likely to respond with validated CLIA certified assay using a patented biomarker. Pipeline & platform enable multiple shots on goal: Lead candidate opportunities in multiple metastatic tumor indications. Targeted Oncolytic Peptide platform – produces pipeline of products targeted to other cell receptors and other cancer types. Significant near term value creation milestones including partnership or ex-US license opportunity in HCC – the 2nd leading cause of cancer deaths in Asia. The A28 team has more than 75 years of relevant scientific, drug development and business experience; Advisors have brought more than a dozen drugs through approval and sold biotech businesses for more than $10 billion in just the past two years.